Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term study of K-877

Next Previous
X
Search
Trial Profile

Long-term study of K-877

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemafibrate (Primary)
  • Indications Hypertriglyceridaemia; Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PROVIDE
  • Sponsors Kowa

    • Most Recent Events

    • 03 Jan 2018 Primary endpoint (Percentage change in fasting serum TG level from the baseline at the final evaluation over 24 weeks) has been met, according to results published in the Diabetes Care.
    • 03 Jan 2018 Results assessing the long-term efficacy and safety of pemafibrate treatment for over 24 weeks in patients with type 2 diabetes comorbid with hypertriglyceridemia, were published in the Diabetes Care.
    • 06 Jun 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top